<DOC>
	<DOCNO>NCT00260793</DOCNO>
	<brief_summary>The purpose research study see subject Parkinson 's disease experience motor fluctuation ( `` '' `` '' state ) dyskinesias ( involuntary excessive movement ) would benefit high dose Requip compare maximum FDA approve dose dopamine agonist drug ( include Requip , Mirapex , Permax ) . Requip use study investigational , mean approve US Food Drug Administration ( FDA ) dose level .</brief_summary>
	<brief_title>Open Label High Dose Ropinirole ( Requip ) Study Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Patients must give write informed consent prior specific study procedure . Males females ; female childbearing age currently pregnant must agree use medically accept method contraception throughout study . Age great equal 25 year . Patients must maximum dose dopamine agonist drug ( pergolide 4mg/day , pramipexole 4.5 mg/day ropinirole 24mg/day ) . Stable dose medication 4 week . Current hallucination . History disable hallucination hallucination past require treatment . Troublesome edema ( swell ) . Unstable depression . Female pregnant lactating . Use investigational drug last 30 day . Other inclusion exclusion criterion evaluate physician .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
	<keyword>Ropinirole</keyword>
	<keyword>Parkinson 's disease</keyword>
	<keyword>dopamine agonist</keyword>
</DOC>